The minimal PSA threshold to improve the [18F]fluciclovine PET/CT DR in BCR PCa patients was already investigated by Armstrong et al., who suggested a PSA cut-off of 2.10 ng/mL [26]. This evidence concerns the gene KLK3 and posterior cortical atrophy.